Kalaris Therapeutics Inc (KLRS) Stock Price, Quote & News

Company Profile

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeuti...

Industry: Biotechnology

Sector: Healthcare

Phone: 650-249-2727

Website: kalaristx.com

Address:

400 Connell Drive, Suite 5500 Berkeley Heights, Berkeley Heights, United States

focafoca99 Apr. 11 at 8:58 PM

$KLRS said CFO Matthew Gall will step down on April 14, with chief accounting officer Brett Hagen taking over as principal financial officer.

0 · Reply

OfficialStocktwitsUser Apr. 8 at 1:34 AM

$KLRS RSI: 27.94, MACD: -0.8713 Vol: 1.46, MA20: 7.04, MA50: 8.58 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

SuperGreenToday Apr. 7 at 2:02 AM

$KLRS

0 · Reply

ApolloAlerts Mar. 19 at 10:15 PM

$KLRS

0 · Reply

Orlandotrader Mar. 3 at 6:12 PM

$KLRS Come to PaPa

0 · Reply

BillionerOfKing Feb. 24 at 8:07 PM

$KLRS Current Stock Price: $10.76

0 · Reply

char13 Feb. 19 at 10:21 AM

$KLRS more than 100m market cap and a director bot a massive stake recently

0 · Reply

OfficialStocktwitsUser Feb. 16 at 11:49 AM

$KLRS RSI: 38.19, MACD: 0.0620 Vol: 0.52, MA20: 9.30, MA50: 8.82 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

OfficialStocktwitsUser Feb. 3 at 12:10 PM

$KLRS RSI: 54.46, MACD: 0.2618 Vol: 0.56, MA20: 9.22, MA50: 8.33 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

1 · Reply

WallStArb Jan. 2 at 3:21 PM

$KLRS broke down under support - next data 12 - 18 months out

2 · Reply

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

Dec 17, 2025, 5:59 PM EST - 4 months ago

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

Dec 17, 2025, 4:01 PM EST - 4 months ago

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

Nov 24, 2025, 8:00 AM EST - 5 months ago

Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference

Nov 12, 2025, 8:00 AM EST - 5 months ago

Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 3, 2025, 7:30 AM EST - 5 months ago

Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer

Oct 30, 2025, 8:00 AM EDT - 5 months ago

Kalaris to Present at Stifel 2025 Annual Healthcare Conference

Sep 15, 2025, 3:26 PM EDT - 7 months ago

UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration

Sep 15, 2025, 8:00 AM EDT - 7 months ago

Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration

Aug 13, 2025, 8:00 AM EDT - 8 months ago

Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jun 2, 2025, 8:00 AM EDT - 11 months ago

Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference

May 23, 2025, 11:03 AM EDT - 11 months ago

Kalaris to Participate at Stifel Ophthalmology Forum

May 14, 2025, 8:00 AM EDT - 11 months ago

Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee

Mar 18, 2025, 4:21 PM EDT - 1 year ago

Kalaris Announces Closing of Merger with AlloVir

ALVR

focafoca99 Apr. 11 at 8:58 PM

$KLRS said CFO Matthew Gall will step down on April 14, with chief accounting officer Brett Hagen taking over as principal financial officer.

0 · Reply

OfficialStocktwitsUser Apr. 8 at 1:34 AM

0 · Reply

SuperGreenToday Apr. 7 at 2:02 AM

$KLRS

0 · Reply

ApolloAlerts Mar. 19 at 10:15 PM

$KLRS

0 · Reply

Orlandotrader Mar. 3 at 6:12 PM

$KLRS Come to PaPa

0 · Reply

BillionerOfKing Feb. 24 at 8:07 PM

$KLRS Current Stock Price: $10.76

0 · Reply

char13 Feb. 19 at 10:21 AM

$KLRS more than 100m market cap and a director bot a massive stake recently

0 · Reply

OfficialStocktwitsUser Feb. 16 at 11:49 AM

0 · Reply

OfficialStocktwitsUser Feb. 3 at 12:10 PM

1 · Reply

WallStArb Jan. 2 at 3:21 PM

$KLRS broke down under support - next data 12 - 18 months out

2 · Reply

WallStArb Dec. 29 at 4:18 PM

$KLRS looking for 3.50 - 4.20

0 · Reply

WallStArb Dec. 29 at 3:07 PM

$KLRS expect this to trade back down near net cash out 90d - this never had a PIPE when they did the reverse so I expect the $50M essentially covers that now - curious why the investors didn’t do the pipe prior to the data - now it’s a 12 month wait for next major data points

0 · Reply

ZenithZulu Dec. 25 at 2:57 PM

$KLRS Forward returns depend heavily on whether management can deliver consistent operational results. Execution gaps should narrow meaningfully over coming quarters. Visible traction across segments would strengthen the thesis. The next phase will be defined less by vision and more by delivery.

0 · Reply

SuperGreenToday Dec. 24 at 9:43 AM

$KLRS

0 · Reply

JarvisFlow Dec. 23 at 12:40 PM

Chardan Capital has updated their rating for Kalaris Therapeutics ( $KLRS ) to Buy with a price target of 19.

0 · Reply

DonCorleone77 Dec. 23 at 10:49 AM

$KLRS Kalaris Therapeutics initiated with a Buy at Chardan Chardan initiated coverage of Kalaris Therapeutics with a Buy rating and $19 price target. The firm cites the commercial potential of the company's lead candidate TH103 in wet age-related macular degeneration for the Buy rating. Kalaris has further opportunities to expand into diabetic retinopathy, diabetic macular edema, and retinal vein occlusion, the analyst tells investors in a research note.

0 · Reply

StockScanners Dec. 20 at 6:29 PM

$KLRS reached 1.88

0 · Reply

WallStArb Dec. 19 at 9:06 PM

$KLRS I don’t own this anymore and I am not interested in it any longer was a one time trade. Started to accumulate a couple new names and added to $ASMB thiscmorning for spring updates and data points

2 · Reply

Orlandotrader Dec. 18 at 2:15 PM

$KLRS Would not be surprised if this runs up today based on the Great Placement of 10$. Someone payed up for this. Not sure why. Still trying to determine dosing.

1 · Reply

briefingcom Dec. 18 at 1:46 PM

$KLRS: Kalaris Therapeutics prices $50.0 mln private placement consisting of common stock and warrants https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20251218042942KLRS&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

0 · Reply

Market Cap	144.45M
Revenue (ttm)	0.00
Net Income (ttm)	-43.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	125,755
Avg Vol	63,424
Day's Range	N/A - N/A
Shares Out	22.93M
Stochastic %K	56%
Beta	0.18
Analysts	Strong Sell
Price Target	$19.00